NQO1 and pancreatic neoplasm: Since the cancer toxicity of KP372-1 has been reported to have a potential dependence on NQO1 expression (26), we next examined the efficacy of combining the PARPi rucaparib with KP372-1 in NSCLC, pancreatic cancer, and breast cancer cells, which were reconstituted or knocked out for NQO1 expression, treated with or without dicoumarol (Figures 1F–K).